Collegium Pharmaceutical (COLL) Net Cash Flow (2014 - 2026)

Collegium Pharmaceutical's Net Cash Flow history runs 13 years deep, the most recent figure standing at $37.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 82.59% year-over-year to $37.4 million in Q1 2026; TTM through Mar 2026 was $172.5 million, a 253.21% increase from a year earlier, with the FY2025 full-year figure at $155.5 million, up 208.48% from the prior year.
• Net Cash Flow eased to $37.4 million in Q1 2026 per COLL's latest filing, from $81.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $95.8 million in Q1 2023 and bottomed at -$108.9 million in Q3 2024.
• The 5-year median for Net Cash Flow is $16.0 million (2022), against an average of $5.9 million.
• Biggest YoY gain for Net Cash Flow was 680.51% in 2022; the steepest drop was 1019.16% in 2022.
• Year by year, Net Cash Flow stood at $39.6 million in 2022, then plunged by 149.5% to -$19.6 million in 2023, then surged by 261.37% to $31.6 million in 2024, then soared by 156.79% to $81.2 million in 2025, then sank by 53.92% to $37.4 million in 2026.
• Per Business Quant, the three latest COLL Net Cash Flow figures stand at $37.4 million (Q1 2026), $81.2 million (Q4 2025), and $32.8 million (Q3 2025).